STAT Plus: Study of AstraZeneca’s top-selling cancer drug stopped early for ‘overwhelming’ benefit
ADOBE
AstraZeneca halted a study of its lung cancer treatment Tagrisso after observing what the company called an “overwhelming” benefit.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario